IVIg to SC Ig: Switching Immunoglobulin Therapies for Primary Immunodeficiency
- For people living with primary immunodeficiency (PI), immunoglobulin replacement therapy (Ig) is a cornerstone of treatment.
- One of the biggest shifts when moving from IVIg to scig is the level of personal responsibility involved.
- Side effects are a common reason people consider changing how they receive immunoglobulin therapy.IVIg is more frequently enough associated with systemic side effects, such as headaches, fatigue, fever,...
For people living with primary immunodeficiency (PI), immunoglobulin replacement therapy (Ig) is a cornerstone of treatment. It helps prevent serious infections, reduces hospitalizations, and supports long-term health.The immunoglobulin used in treatment comes from donated human plasma, and it can be administered in two different ways: through an intravenous infusion (IVIg), typically at a hospital or infusion center, even though some people get IVIg at home, or through subcutaneous infusions (SCIg) that are usually done at home.Research consistently shows that both IVIg and SCIg are effective at reducing infections and improving quality of life when used as prescribed.Once stable and therapeutic antibody levels are reached, the outcomes are similar, says Vincent Tubiolo, MD, an allergy, asthma, and immunology specialist in Santa Barbara, California. “The main reasons moast patients switch from IVIg to SCIg is related to cost, convenience, and side effects,” says Dr.Tubiolo. The decision is a personal choice that works best when made through shared decision-making with your healthcare team. Here’s what you need to know.
Level of Duty
Table of Contents
One of the biggest shifts when moving from IVIg to scig is the level of personal responsibility involved. “When patients switch from IVIg to SCIg, the most intimidating process is the reality of administering your own infusion,” says Rekha Raveendran, MD, an allergist-immunologist at the Ohio State University Wexner Medical Center in Columbus. With IVIg, infusions are administered by healthcare professionals in a medical setting, whereas SCIg is self-administered at home after training. While many people appreciate the flexibility of home treatment, it also means taking responsibility for setting up infusions, monitoring reactions, and keeping supplies organized. To help patients feel more comfortable with this option, nursing staff comes to the patient’s house to teach them how to infuse, says Dr.Raveendran.”They typically receive one-on-one training provided through the specialty pharmacy, with nursing staff coming to the patient’s home to help teach them and troubleshoot issues. They typically will have at least three visits before they are expected to do their own infusions,” she says. SCIg also requires managing deliveries of medication, which need to be refrigerated until use. The necessary supplies include infusion tubing, needles, antiseptic wipes, and sometimes an infusion pump. You’ll be in charge of connecting the syringe and tubing to the pump in a sanitary way and inserting and removing the needles from your skin.For some people, this level of involvement feels empowering, but for others, it can feel overwhelming.That’s why it’s important to talk through concerns with your healthcare provider before making the switch.
Side Effects of IVIg vs. SCIg
Side effects are a common reason people consider changing how they receive immunoglobulin therapy.IVIg is more frequently enough associated with systemic side effects, such as headaches, fatigue, fever, chills, nausea, or flulike symptoms, says raveendran. “Rarely, side effects can even include aseptic meningitis,” she says. Aseptic meningitis is inflammation of the protective membranes around the brain and spinal cord that can cause fever, severe headache, nausea, and vomiting. “Pretreatment with steroids…”
Primary Immunodeficiency Treatment: IVIg vs. SCIg
Please note: The source text is considered untrusted and has been independently verified using authoritative sources.Data current as of 2026/01/18 01:42:18 is used.
What are IVIg and SCIg?
Both intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are treatments used to replace missing antibodies in individuals with primary immunodeficiency (PI). The National Institute of Allergy and Infectious Diseases (NIAID) defines primary immunodeficiencies as a group of over 400 conditions in which part of the immune system is missing or functioning improperly. Both therapies aim to restore IgG levels, improving the body’s ability to fight infection. Outcomes are generally comparable once stable IgG levels are achieved with either treatment.
Benefits and Considerations of SCIg (Subcutaneous immunoglobulin)
SCIg offers patients greater flexibility and independence in managing their treatment. A review published in the Journal of Clinical Examination highlights the convenience of SCIg, allowing infusions to be scheduled around personal commitments like work, school, or travel, rather than being dictated by clinic availability. This can lead to improved treatment adherence and overall patient satisfaction. However, SCIg is not suitable for everyone.Individuals with bleeding disorders or those prone to easy bruising should avoid SCIg due to the risk of localized bleeding at the injection site. Furthermore, those who are severely ill or lack the ability to self-administer, or access assistance for administration, may find SCIg impractical.
Benefits and Considerations of IVIg (intravenous Immunoglobulin)
IVIg is administered directly into the bloodstream via an intravenous line. While it carries rare but serious risks related to IV access, such as bloodstream infections, the FDA issued a safety communication in 2024 regarding increased risks of blood clots and stroke associated with IVIg products. IVIg is more likely to cause systemic side effects, such as headaches and flu-like symptoms, compared to SCIg. Some patients prefer the structured environment of a clinic-based IVIg infusion and the reassurance of medical supervision, particularly if they experiance anxiety related to self-infusion.
Patient choice and Adherence
The Infectious Diseases Society of america (IDSA) guidelines emphasize the importance of patient involvement in treatment decisions. Patients with PI generally demonstrate better adherence and satisfaction when they actively participate in choosing between ivig and SCIg, irrespective of which method they ultimately select.
Side Effects Comparison
scig commonly causes mild skin reactions at the injection site, which frequently enough improve over time. IVIg, on the other hand, is associated with a higher incidence of systemic side effects like headaches or flu-like symptoms. The specific side effect profile can vary between individuals and immunoglobulin products.
Disclaimer: This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.